BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 10, 2005
View Archived Issues
Nexia Agreement For Asset Sale Awaiting OK From Shareholders
Canadian firm Nexia Biotechnologies Inc. entered an agreement to sell all of its assets and operations to a subsidiary of privately held PharmAthene Inc. for $18 million in cash and preferred shares and warrants. (BioWorld Today)
Read More
Alteon Brings In $10M For Phase II Alagebrium Trials
Read More
New Chemo Approach Raises Bar In Cancer Drug Research
Read More
Depomed Bringing In $22M For Trials, Marketing Of GR Products
Read More
Other News To Note
Read More